BOSTON, June 17, 2024 /PRNewswire/ -- Day Zero
Diagnostics, Inc. (DZD), an infectious disease diagnostics
company harnessing the power of whole-genome sequencing and AI to
combat the rise of antibiotic-resistant infections, presented three
presentations at the 2024 ASM Microbe conference. ASM Microbe is
the premier annual conference organized by the American Society of
Microbiology and takes place June 13-17,
2024 in Atlanta, GA.
![Day Zero Diagnostics (PRNewsfoto/Day Zero Diagnostics, Inc.) Day Zero Diagnostics (PRNewsfoto/Day Zero Diagnostics, Inc.)](https://mma.prnewswire.com/media/1742795/Day_Zero_Diagnostics_Logo.jpg)
Dr. Jason Wittenbach, Director of
Data Science at DZD, presented, as part of the "Rapid AST and
Diagnostics Methods" session, results of a study demonstrating
DZD's ability through Keynome®, its machine learning
computational platform, to decipher bacterial whole genomes
retrieved from patient blood samples and to predict antimicrobial
resistance comprehensively and accurately, without the use of
culture. In addition, Dr. Wittenbach presented, as part of the
symposium "What Will AI Provide to Clinical Microbiology and Public
Health in 10 Years", a large-scale research performed in
collaboration with UC Irvine, demonstrating concordance of Keynome
gAST results from pathogen WGS inputs – with phenotypic AST.
"Unlike traditional approaches for inferring resistance from
pathogen genomes that rely on the detection of resistance genes
previously identified by scientists, the machine learning
algorithms that power Keynome have deduced the drivers of
resistance and susceptibility on their own by sifting through a
database of over 48,000 bacterial genomes paired with over 450,000
susceptibility test results," said Dr. Wittenbach.
Also, Dr. Nicole Billings, Sr.
Director of Lab Services and Platform Expansion at DZD, presented
results from the feasibility phase of an ongoing clinical study
demonstrating DZD's enrichment process (Pathovate™)
capability of recovering clinical pathogen genomes directly from
blood for whole genome sequencing, as well as its novel algorithms
(Keynome) for bacterial or fungal ID and AST prediction using
machine learning.
About Day Zero Diagnostics
Day Zero Diagnostics, Inc., based in Boston, is pioneering a new class of
infectious disease diagnostics using whole-genome sequencing and
artificial intelligence to revolutionize how the world fights the
growing threat of antimicrobial resistance. The company's mission
is to change the way infectious diseases are diagnosed and treated
by rapidly identifying both the species and the antimicrobial
susceptibility profile of severe infections directly from a
clinical sample without the need for a culture. Day Zero also
offers a family of lab services under the epiXact® brand
that utilize proprietary technologies to assist healthcare
organizations manage infection outbreaks, investigate organisms of
interest, and make high-impact decisions. Day Zero Diagnostics was
founded in 2016 by a team of clinicians and scientists from
Harvard University and the
Massachusetts General Hospital. The company has been recognized as
a leading innovator by CARB-X, UCSF Health, American Association of
Clinical Chemistry, MedTech Innovator, TedMed Hive, HealthTech
Arkansas, and MassChallenge HealthTech. Follow DZD on
X (formerly Twitter) and LinkedIn.
Research reported in this press release is supported by CARB-X.
CARB-X's funding for this project is provided in part with federal
funds from the U.S. Department of Health and Human Services;
Administration for Strategic Preparedness and Response; Biomedical
Advanced Research and Development Authority; under agreement
number: 75A50122C00028, and by awards from Wellcome (WT224842) and
Germany's Federal Ministry of
Education and Research (BMBF). The content of this press release is
solely the responsibility of the authors and does not necessarily
represent the official views of CARB-X or any of its funders.
Media contact
View original content to download
multimedia:https://www.prnewswire.com/news-releases/day-zero-diagnostics-presents-direct-from-blood-rapid-antimicrobial-susceptibility-testing-at-asm-microbe-302173229.html
SOURCE Day Zero Diagnostics, Inc.